Phibro Animal Health shares surge 21.95% intraday after raising 2026 guidance and reporting strong Q2 results.

Phibro Animal Health surged 21.95% intraday following strong Q2 2026 results and raised full-year guidance. The company reported 21% revenue growth to $373.9 million, with animal health sales up 26%, driven by the MFA acquisition and improved margins. Adjusted EBITDA increased 41% to $19.9 million, and the firm raised 2026 sales guidance to $1.45–1.5 billion and EPS to $2.08–$2.32. The stock’s sharp rise aligned with the premarket 16.82% jump after exceeding earnings and revenue forecasts, reflecting investor confidence in the company’s strategic integration of MFA, improved margins, and leadership transition.